Shares of Endo International PLC (NASDAQ:ENDP) have been assigned an average recommendation of “Hold” from the twenty-three research firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $17.02.

A number of brokerages have weighed in on ENDP. William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Guggenheim began coverage on shares of Endo International PLC in a research note on Saturday. They set a “hold” rating and a $12.00 target price for the company. Royal Bank Of Canada set a $15.00 target price on shares of Endo International PLC and gave the company a “hold” rating in a research note on Monday, June 12th. BidaskClub lowered shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Cantor Fitzgerald began coverage on shares of Endo International PLC in a research note on Friday. They set a “neutral” rating and a $12.00 target price for the company.

Shares of Endo International PLC (NASDAQ:ENDP) traded up 2.60% during mid-day trading on Monday, hitting $11.05. The stock had a trading volume of 4,932,471 shares. The firm’s market cap is $2.47 billion. The stock’s 50-day moving average price is $12.25 and its 200-day moving average price is $12.75. Endo International PLC has a 52-week low of $9.70 and a 52-week high of $24.93.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.13. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the business earned $1.08 EPS. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. On average, analysts anticipate that Endo International PLC will post $3.58 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/19/endo-international-plc-endp-given-average-recommendation-of-hold-by-analysts.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. increased its position in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares during the period. Point View Wealth Management Inc. increased its position in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares during the period. Perceptive Advisors LLC bought a new position in Endo International PLC during the fourth quarter valued at approximately $213,000. Tyers Asset Management LLC bought a new position in Endo International PLC during the fourth quarter valued at approximately $375,000. Finally, Capital Fund Management S.A. bought a new position in Endo International PLC during the first quarter valued at approximately $260,000. 93.30% of the stock is owned by institutional investors and hedge funds.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.